ClinicalTrials.gg
CompletedNCT06775041Updated Oct 2, 2026

Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)

A Phase 2 interventional study of Progerinin and Lonafarnib in Hutchinson-Gilford Progeria Syndrome, sponsored by PRG Science & Technology Co., Ltd.. Completed at 1 site in United States. Open to participants aged 1 Year and older. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by PRG Science & Technology Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 2, 2026Now CompletedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
1 Year and older
Sex
All
01

Study summary

Researchers will compare treatment with progerinin plus lonafarnib vs lonafarnib alone to assess optimal dosing, safety, tolerability, and pharmacokinetics in patients with Hutchinson-Gilford Progeria Syndrome (HGPS). Subjects in the randomized study arms will continue to take the standard of care (SOC), lonafarnib, and will be randomized to either take SOC alone or in combination with progerinin.

Read the detailed description

During this trial, a total of 10 subjects will be randomized in a 4:1 ratio to receive treatment with progerinin plus lonafarnib vs lonafarnib alone. Dose escalation will occur through intra-subject dose titration. Two ascending doses of progerinin will be assessed. The dose levels proposed in this study were determined using body weight based on adult doses assessed in previously completed studies, and on a simulated population pharmacokinetic (PK) model. If systemic exposures of Progerinin in pediatric patients are lower than those in adults, a dose escalation may be added at the end of the study.

Progerinin will be administered, with food. The study treatment is available in sachets of 250 mg or 350 mg and the doses in the study range from 500 to 1500 mg daily, dosed BID (twice a day).

Lonafarnib is considered as the standard of care (SOC) and all subjects in the randomized study arms will continue taking lonafarnib for the duration of the study. Subjects who are not already taking lonafarnib will also have the opportunity to initiate lonafarnib on this study as part of the lonafarnib naïve arm (separate from the randomized study arms).

02

Conditions studied

  • Hutchinson-Gilford Progeria Syndrome
03

In context

Lead sponsor

PRG Science & Technology Co., Ltd. is the lead sponsor of 5 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Year and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:

  1. Subjects ≥ 1 year of age and weight ≥ 17.6 lb (8 kg).
  2. Subject must have confirmatory mutational analysis showing the classic HGPS mutation (c. 1824 C>T), nonclassic HGPS, Zmpset24 gene mutation, or other LMNA mutation (all subjects will havedocumentation of genetic testing prior to enrollment). *Only subjects with progerin producing mutations will be eligible for randomization. Other PL are eligible to enroll as naïve subjects (see note for criterion #5).
  3. Subject must display clinical signs of Progeria as per the clinical trial team.
  4. Subject must be willing and able to come to Boston for appropriate assessments and examinations.
  5. Subject must be taking lonafarnib for at least 4 months prior to enrollment and have no history of grade 3 or 4 side effects that can be probably or possibly attributed to lonafarnib for at least 2 months prior to enrollment.

    Note: Subjects with no prior treatment (i.e., no commercial or managed access program source) with lonafarnib may be enrolled to initiate treatment with lonafarnib monotherapy. These subjects will initiate lonafarnib therapy in preparation for an upcoming phase of the study following the completion of phase 2a. These subjects will be excluded from the analysis of this phase 2a study. These subjects must be at least 12 months of age per lonafarnib package insert.

  6. Subjects must have had no recent fractures or major surgery (within four weeks).
  7. Subject must have adequate organ and marrow function as defined by the following parameters:

    1. Blood: APC (ANC + bands + monocytes) >1,000/µL, >75,000/µL (transfusion independent); >9 g/dL.
    2. Renal: creatinine ≤ 1.5 times normal for age or (GFR) >70 mL/min/1.73m2.
    3. Hepatic: ≤1.5x for age; Serum Glutamic Pyruvic Transaminase () (Alanine Transaminase, [ALT]) \< and Serum Glutamic-Oxaloacetic Transaminase (SGOT) (Aspartate Aminotransferase, [AST]) ≤ 2.5x normal range for age.
  8. The subject is willing to provide written informed assent form, when possible, to participate in the study after reading the informed assent form and the information provided and has had the opportunity to discuss the study with the investigator or designee. Additionally, the subject's legally authorized guardian (LAR) is willing to provide written .
  9. The subject is able to communicate satisfactorily with the investigator and to participate in, and comply with, the requirements of the study.
  10. The subject (or LAR) is able to understand the nature of the study and any potential hazards associated with participating in it.
  11. Negative pregnancy test for female subjects of and those who have not been surgically sterilized or who do not have verbal or laboratory confirmation of two years status. Women of childbearing potential (WOCBP) and Women of non-childbearing potential are eligible to participate. Women of childbearing potential should use an acceptable method of and agree to continue to use this method for the duration of the study and for 90 days after taking the last dose of Progerinin.

Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, implanted, or injected) in conjunction with a barrier method (WOCBP only) (e.g., diaphragm, cervical cap, male condom, and female condom and spermicidal foam, sponges, and film), female subject/partner's use of an intrauterine device (IUD), or if the female subject/partner is surgically sterile (e.g., bilateral tubal ligation, hysterectomy) or two years postmenopausal at time of screening. All male subjects/partners (excluding men who have been sterilized) must agree to consistently and correctly use a condom for the duration of the study and for 90 days after taking the study drug. In addition, subjects may not donate sperm for the duration of the study and for 90 days after taking study drug.

Exclusion criteria

Exclusion Criteria:

Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:

  1. Other than the drugs used in this protocol, other drugs targeted to treat Progeria are excluded. Drugs to treat symptoms of Progeria are permitted.
  2. Subjects are taking medications that significantly affect the metabolism of Progerinin.
  3. Subjects with an active bleeding diathesis or on oral anti-vitamin K medication (except low dose coumadin).
  4. Subjects who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:

    1. known severely impaired lung function
    2. active (acute or chronic) or uncontrolled severe infections.
    3. liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
    4. history of or documented by history and confirmed by serology if positive for history.
  5. Other concurrent severe and/or uncontrolled medical disease that could compromise participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension, severe infection, severe malnutrition, chronic liver or renal disease, active upper GI tract ulceration).
  6. A known history of (HIV) seropositivity or known immunodeficiency.
  7. Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of Progerinin (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection). A nasogastric tube (NG tube) or gastric tube (G tube) is allowed.
  8. Subjects who have known or suspected to any of the included in the formulation should not be treated.
  9. Subjects who have used marijuana or other (Tetrahydrocannabinol) THC containing products either recreationally or for medical purposes within three months prior to entering the study.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Progerinin + Lonafarnib

    Subjects who have successfully completed the Screening phase will enter the treatment phase of the study and be randomized to a treatment arm. Subjects randomized to the progerinin + lonafarnib arm will take progerinin at a dose dependent on their body weight and will continue taking lonafarnib per the package insert. For each dose cohort, subjects will complete a 28-day treatment period of toxicity assessment, and a minimum four-month treatment period for plasma progerin evaluation. After the last subject completes the toxicity assessment period, the independent Data Monitoring Committee (iDMC) will meet to confirm that subjects can be escalated to the next dose. All subjects will remain on the current dose until the iDMC decision is confirmed. Each subject will only be escalated to the next dose after their 4-month (±2 weeks) plasma progerin sample is collected.

    Drug: Progerinin · Drug: Lonafarnib

  • Other
    Lonafarnib Naïve

    Subjects with no prior treatment with lonafarnib (i.e., no commercial or managed access program source) may be enrolled to initiate treatment with lonafarnib monotherapy. These subjects will initiate lonafarnib therapy in preparation for an upcoming phase of the study following the completion of phase 2a. These subjects will be excluded from the analysis of this phase 2a study. They will come to the study site for a baseline visit and at one year for assessment as described later in this protocol.

    Drug: Lonafarnib

  • Active comparator
    Lonafarnib

    Subjects in the main study arms (Progerinin + Lonafarnib and non-naïve Lonafarnib) will continue taking lonafarnib per the package insert. Subjects randomized to the lonafarnib alone arm will not take progerinin during this study.

    Drug: Lonafarnib

Interventions

  • Dosing will be determined based on body weight. Dosing ranges from 500mg to 1500mg daily. Progerinin is available in sachets of 250 mg or 350 mg for oral use.

  • Lonafarnib is considered as the standard of care (SOC). Subjects in the randomized arms will continue taking lonafarnib per the package insert. Subjects in the lonafarnib naïve arm will initiate lonafarnib as per FDA-approved study 07-01-7505.

06

What researchers measure

Primary outcomes

  1. Change from baseline in plasma progerin concentration

    Time frame: Baseline and Month 4 of each cohort

  2. Incidence of Dose Limiting Toxicities (DLTs)

    Time frame: From baseline to follow-up (approximately 13 months)

  3. Incidence and severity of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: From baseline to follow-up (approximately 13 months)

  4. Incidence of withdrawals due to Adverse Events (AEs)

    Time frame: From baseline to follow-up (approximately 13 months)

  5. Incidence of Treatment-Related Adverse Events

    Time frame: From baseline to follow-up (approximately 13 months)

  6. Incidence of Serious Adverse Events (SAEs)

    Time frame: From baseline to follow-up (approximately 13 months)

  7. Change/shifts in laboratory values from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  8. Change in blood pressure from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  9. Change in heart rate from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  10. Change in respiratory rate from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  11. Change in temperature from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  12. Change in Electrocardiogram (ECG) parameter, ventricular rate (beats per minute), from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  13. Change in Electrocardiogram (ECG) parameter, PR interval (msec), from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  14. Change in Electrocardiogram (ECG) parameter, QRS interval (msec), from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  15. Change in Electrocardiogram (ECG) parameter, QT interval (msec), from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  16. Change in Electrocardiogram (ECG) parameter, QTc interval (msec), from baseline

    Time frame: From baseline to follow-up (approximately 13 months)

  17. Maximum observed plasma drug concentration (Cmax)

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort

  18. Apparent terminal elimination half-life (t1/2)

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2

  19. Time to maximum observed plasma drug concentration (Tmax)

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2

  20. Area under the plasma drug concentration-time curve (AUC) from time 0 to the end of the dosing period (AUC0-τ)

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2

  21. Clearance (CL)

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of cohort1 & cohort 2

  22. Covariates: Age

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort

  23. Covariates: Body weight

    Time frame: Baseline, and pre-dose (0 hr) and 2-5 hr post-dose at Month 4 of each cohort

07

Study locations

1 site
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Mar 2026, 14 months.

Completion moved once since we started tracking on Sep 25, 2026: Mar 2026 → Apr 2026, on Oct 2, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Jan 14, 2025
StartActual
Jan 13, 2025
Primary completionActual
Mar 30, 2026
CompletionActual
Apr 30, 2026was Mar 2026
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 2, 2026
Study completion
Mar 2026→Apr 30, 2026 (actual)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Active, not recruiting→Completed
    Study completion Mar 2026→Apr 30, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06775041
Lead sponsor
PRG Science & Technology Co., Ltd.
Responsible party
Sponsor
First posted
Jan 14, 2025
Start date
Jan 13, 2025
Primary completion
Mar 30, 2026
Completion
Apr 30, 2026
Last update
Oct 2, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Progerinin

Start the discussion